Publication | Open Access
Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma
60
Citations
41
References
2021
Year
Our preclinical and clinical data suggest that AT-101 overcomes resistance by targeting CSCs pathways suggesting a novel mechanism of action of AT101 in patients with GEC.
| Year | Citations | |
|---|---|---|
Page 1
Page 1